CytomX Therapeutics, Inc.
corporate_fare Company Profile
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for CTMX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-27, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CTMX spans 8-K, 10-Q, PRE 14A, 424B5.
Recent high-impact activity:
- FDA Grants Fast Track to CytomX's Varseta-M for Colorectal Cancer
- Varseta-M Phase 1 Enrollment Complete, Data by Year-End; Q2 Revenue Plunged 92%
- CytomX Q2 Revenue Plunges to $1.42M, Missing Estimates by 88%
- CytomX Q2 2026: Cash Runway to H2 2028, Varseta-M Registrational Study Planned for 1H 2027
- CytomX Q2 2026: Cash Runway to H2 2028, Regeneron Deal Expanded, Varseta-M Dose Optimization Complete
Financial Snapshot
Short Interest & Short Volume
11.99 days to coverFINRA reported short interest of 45,246,966 shares in CTMX as of the October 30, 2026 settlement, a 5.7% increase from the prior period — about 12.0 days to cover at its recent average daily volume. On November 20, 2026, 67.7% of CTMX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.